Beranda › Melanoma Uveal › Ohio
Uji klinis Melanoma Uveal di Ohio
8 studi untuk Melanoma Uveal mencari peserta di lokasi di Ohio.
Kota di Ohio
Teks studi resmi (Bahasa Inggris)
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- Cleveland Clinic, Cleveland
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07804186Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
- The Ohio State University, Columbus
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06070012Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- University of Cincinnati Cancer Center, Cincinnati
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Jun 2026 · NCT03947385ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mei 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Cole Eye Institute-9500 Euclid Ave, Cleveland
- Ohio State Eye and Ear Institute, Columbus
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- The Ohio State University, Columbus
Menerima pesertaFase 2/3
Semua usia · Semua jenis kelamin · Diperbarui 2 Apr 2026 · NCT06581406Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- The Ohio State University Wexner Medical Center, Columbus
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Semua usia · Semua jenis kelamin · Diperbarui 9 Mar 2026 · NCT04792463A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Case Comprehensive Cancer Center, Cleveland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2025 · NCT06805825Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.